1Bawarshi RN, Hussain AA, Crooks PA. Nasal absorption and metabolism of progesterone and 17β-estradiol in the rat[J]. Drug Metab Dispos, 1989, 17(3): 248 - 254.
2Bawarshi RN, Hussain AA, Crooks PA. Nasal absorption of 17α-ethinyloestradiol in the rat[J]. J Pharm Pharmacol, 1989, 41(3): 214-215.
3Kumar TC, Shah RS, Chitlange SM, et al. Effects of intranasal administration of norethisterone on folliculogenesis, cervical mucus, vaginal cytology,endometrialmorphology and reproductive-endocrine profile in women [ J ].Contraception, 1991, 44(3): 245- 267.
4Hussain AA, Kimura R, Huang CH. Nasal absorption of testosterone in rats[J]. J Pharm Sci, 1984, 73(9): 1300- 1301.
5Shahiwala A, Misra A. Nasal delivery of levonorgestrel for contraception: an experimental study in rats[J]. Fertil Steril, 2004, 81( 1 ): 893- 898.
6Pavis H, Wilcock A, Edgecombe J, et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer[J]. J Pain Symptom Manage, 2002, 24(6): 598- 602.
7Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients[J]. Pain, 2003, 106(3): 309-315.
8Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study[J].Pain, 2004, 108(1-2): 17-27.
9Chou KJ, Donovan MD. The distribution of local anesthetics into the CSF following intranasal administration[J]. Int J Pharm, 1998, 168(2): 137.
10Gozes I, Bardea A, Reshef A, et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide[ J]. Proc Natl Acad Sci USA, 1996, 93(1): 427-432.
